Vital Signs - Are Biosimilars On the U.S. Horizon?

Vital Signs - Are Biosimilars On the U.S. Horizon?

 

RELEASE DATE
23-Jun-2008
REGION
North America
Research Code: 9561-00-66-00-00
SKU: HC00533-NA-MR_04005
AvailableYesPDF Download

$1,500.00

Special Price $1,125.00 save 25 %

In stock
SKU
HC00533-NA-MR_04005

$1,500.00

$1,125.00save 25 %

DownloadLink
ENQUIRE NOW

Description

This issue of Vital Signs, released on June 23, 2008, provides an strategic overview of the issues surrounding generic biotechnology drugs and their approval pathway in the U.S. Additionally, a company spotlight is provided for InNexus Biotechnology, a biotechnology drug development company focused on next-generation monoclonal antibodies. Reimbursement and regulatory news from the FDA is also provided for the week of June 9, 2008.

Table of Contents

This week's issue:

Related Research
This issue of Vital Signs, released on June 23, 2008, provides an strategic overview of the issues surrounding generic biotechnology drugs and their approval pathway in the U.S. Additionally, a company spotlight is provided for InNexus Biotechnology, a biotechnology drug development company focused on next-generation monoclonal antibodies. Reimbursement and regulatory news from the FDA is also provided for the week of June 9, 2008.
More Information
No Index Yes
Podcast No
Industries Healthcare
WIP Number 9561-00-66-00-00
Is Prebook No